Kiniksa Pharmaceuticals International, plc
KNSA
Hisse Senetlerindeki Sıralama
#2964
Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company,... Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, develops and commercializes medical therapies in the United States, the United Kingdom, and internationally. The company offers ARCALYST, an interleukin-1alpha and 1beta cytokine trap for the treatment of recurrent pericarditis, a chronic autoinflammatory cardiovascular disease and cardiac sarcoidosis. It also develops KPL-387, an investigational and fully human immunoglobulin G2 monoclonal antibody, which is Phase 2/3 clinical trial for the treatment of recurrent pericarditis; and KPL-116, a Fc-modified immunoglobulin G2 monoclonal antibody, which is in pre-clinical stage. The company was formerly known as Kiniksa Pharmaceuticals, Ltd. and changed its name to Kiniksa Pharmaceuticals International, plc in June 2024. Kiniksa Pharmaceuticals International, plc was incorporated in 2015 and is based in London, the United Kingdom.
Hisse Fiyatı
$79.61
Son senkronizasyon: 2026-10-19
Piyasa Değeri
$6.21B
Değişim (1 gün)
1.30%
Değişim (1 yıl)
104.18%
Ülke
GB
Ticaret Kiniksa Pharmaceuticals International, plc (KNSA)
Kategori
Healthcare
Kiniksa Pharmaceuticals International, plc (KNSA) için kazanç
Jun 2026 itibarıyla kazanç TTM: $114.25M
Kiniksa Pharmaceuticals International, plc şirketinin en son finansal raporlarına göre, mevcut kazancı $114.25M'dir. 2023 yılında şirket $-16.65M kazanç elde etti, bu 2022 yılındaki $11.03M kazanca göre önceki yıla göre azalma. Bu sayfada gösterilen kazanç, faiz ve vergiler öncesi kazançtır; yani EBIT.
Kiniksa Pharmaceuticals International, plc için kazanç geçmişi 2016 - 2026
Her yılın sonundaki kazanç
| Yıl | Kazanç | Değiştir |
|---|---|---|
| 2026 (TTM) | $114.25M | -416.03% |
| 2024 | $-36.15M | 117.10% |
| 2023 | $-16.65M | -251.02% |
| 2022 | $11.03M | -107.04% |
| 2021 | $-156.54M | 0.20% |
| 2020 | $-156.23M | -4.69% |
| 2019 | $-163.91M | 58.46% |
| 2018 | $-103.44M | 59.46% |
| 2017 | $-64.87M | 171.01% |
| 2016 | $-23.94M | 0.00% |
Benzer şirketler veya rakipler için kazanç
| Şirket | Kazanç | Kazanç Farkı | Ülke |
|---|---|---|---|
| $1.35B | 1,081.48% |
US
|
|
| - | - |
SE
|
|
| - | - |
FR
|
|
| - | - |
IT
|
|
| $1.21B | 954.75% |
HK
|
